John Kastelein

Prof. Dr. John Kastelein is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam with a research interest in ethiology, diagnosis, prevention and treatment of hypertriglyceridaemia, hypercholesteroleamia and low HDL cholesterol. Prof. Kastelein was one of the founders of Amsterdam Molecular Therapeutics Inc. (AMT), a gene therapy company. Recently, Prof. Kastelein also founded Dezima Pharma, a pharmaceutical company that develops assets for the treatment of dyslipidemia. Prof. Kastelein is advisor to pharmaceutical and biotech companies developing cardiovascular disease drugs and principal investigator and advisor to many of the studies trialing new anti-dyslipidemia compounds. Prof. Kastelein is member of several national and international medicine, atherosclerosis and cardiology societies aiming to study, prevent and treat cardiovascular diseases. Prof. Kastelein received the first Lifetime Achievement Award of the Dutch Heart Foundation in 2010 as well as the ZonMW Parel price and the Anitschkov Price from the European Atherosclerosis Society for the best atherosclerosis research in Europe in June 2014. He also was a recipient of the Huibregtsenprice 2014 for the best academic researcher in the Netherlands. Prof. Kastelein has published over 740 research papers in peer reviewed journals.